Sanofi-Aventis faces first US generics for Eloxatin
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries and Hospira have launched their oxaliplatin injection products 50mg/10ml and 100mg/20ml, which will compete with Sanofi-Aventis's chemotherapy medication, Eloxatin. The launches took place after US regulators cleared Teva's 505(b)(2) NDA and Hospira's ANDA.